CNAA & B3005:3TC & ZDV & 1592U89 & 3TC & ZDV & IDV IN HIV 1 INFECTED

感染人类免疫缺陷病毒（HIV）的特点是免疫功能进行性下降，通常持续数年。对于大多数HIV-1感染者来说，这种下降最终导致机会性感染（oi）和/或与获得性免疫缺陷综合征（艾滋病）相关的恶性肿瘤的发展。虽然可以看到长期无艾滋病生存期，但大多数人最终会患上艾滋病并死于疾病。目前，HIV-1感染的治疗包括抗逆转录病毒化疗药物和与艾滋病相关的oi和恶性肿瘤的管理。这是一项III期、随机双盲、平行组、国际多中心研究，旨在评估3TC/ZDV/ 1592U89与3TC/ZDV/IDV相比的抗病毒效果、反应持久性（以HIV-1 RNA测量）和安全性。将评估患者的抗逆转录病毒活性、安全性和治疗方案的耐受性。

Infection with the human immunodeficiency virus (HIV) is characterized by progressive decline in immune function, usually over a period of years. For most HIV-1 infected individuals, this decline with eventually result in the development of opportunistic infections (OIs) and/or malignancies associated with the acquired immunodeficiency syndrome (AIDS). Although a long-term IAIDS-free survival period may be seen, the majority of individuals will eventually develop AIDS and die as a result of their disease. Currently, treatment for HIV-1 infection consists of antiretroviral chemo- therapeutic drugs and the management of the OIs and malignancies associated with AIDS. This is a phase III, randomized double-blind, parallel group, international multicenter study, designed to evaluate the antiviral effect and durability of response (as measured by HIV-1 RNA) and safety of 3TC/ZDV/ 1592U89 as compared to 3TC/ZDV/IDV. Patients will be evaluated for antiretroviral activity, safety, and tolerance of the treatment regimen.